Unrelated donor transplantation for acute myelogenous leukemia in first remission.
Posted by rob on November 20, 2010 under Uncategorized | 
Comments are off for this article
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
Biol Blood Marrow Transplant. 2010 Nov 15;
Authors: Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M
We retrospectively analyzed the outcomes of all AML patients in first remission (n=44; median age=48 years; high-risk cytogenetics=59%) who received unrelated donor hematopoietic cell transplantation with myeloablative conditioning regimen of IV busulfan, fludarabine and anti-thymocyte globulin between January 2002 and November 2009 at our institution. Donor-recipient pairs were matched by high-resolution HLA A, B, C, DRB1 and DQB1 typing (10/10 matches, n=41; 9/10 matches, n=3). With a median follow-up of 34 months, actuarial 3-year event-free survival (EFS) and overall survival (OS) is 70% and 78%, respectively. The 3-year EFS and OS in patients with and without poor risk cytogenetics is similar (63% vs. 82%, p=0.43 and 78% vs. 82%, p=0.89, respectively). The 3-year EFS and OS is also similar in patients above age 55 year versus patients age 55 year or younger (80% vs.67%, p=0.47 and 80% vs. 78%, p=0.81, respectively). One hundred-day and 3-year cumulative incidence of transplant-related mortality is 5% and 15%, respectively. Six patients have relapsed and three of them are alive and in remission after salvage therapy with a median follow up of 23 months. These results indicate that the majority of AML patients eligible for this treatment can achieve long term disease control.
PMID: 21087679 [PubMed - as supplied by publisher]